NRAS and melanoma: In a preclinical study reported by Phadke et al., the results showed that the sequence of immunotherapy and targeted therapy can modulate TME in NRAS‐mutated melanoma, leading to favorable changes such as increased infiltration of TIL and NK cells, and decreased presence of TAMs, MDCSs, and Tregs [505].